Literature DB >> 29716743

FOXO3a Reverses the Cisplatin Resistance in Ovarian Cancer.

Mudan Lu1, Xuan Chen2, Jianping Xiao1, Jingying Xiang1, Lan Yang1, Daozhen Chen3.   

Abstract

OBJECTIVE: Ovarian cancer is one of the most serious disease in female reproductive system. Platinum is the first-line drug for the treatment of ovarian cancer, while the resistance of platinum drug in clinical hindered the relief ovarian cancer. Our previous study found that decreased FOXO3a might be a poor prognosis in human ovarian cancer. In this research, we study whether FOXO3a was involved in the mechanism of platinum drug resistance.
METHODS: The CCK-8 and FACS analysis were used to monitor the survival of ovarian cancer, and the FOXO3a expression was detected by western-blot.
RESULTS: We found that FOXO3a expression upregulated significantly in A2780 compared with A2780/DDP cells with the treatment of platinum. Moreover, overexpression of FOXO3a in ovarian cancer inversed the platinum resistance in ovarian cancer.
CONCLUSION: These observations reminded that the role of FOXO3a might be one of the critical mechanisms in developing platinum drug resistance in ovarian cancer.
Copyright © 2018 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FOXO3a; Ovarian cancer; Platinum drug resistance

Mesh:

Substances:

Year:  2018        PMID: 29716743     DOI: 10.1016/j.arcmed.2018.04.014

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  3 in total

1.  Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low-dose fraction radiation.

Authors:  Lili Zhao; Shihai Liu; Donghai Liang; Tao Jiang; Xiaoyan Yan; Shengnan Zhao; Yuanwei Liu; Wei Zhao; Hongsheng Yu
Journal:  Cancer Med       Date:  2019-04-02       Impact factor: 4.452

2.  SIRT3 promotion reduces resistance to cisplatin in lung cancer by modulating the FOXO3/CDT1 axis.

Authors:  Yang Cao; Ping Li; Haicun Wang; Lei Li; Quanwang Li
Journal:  Cancer Med       Date:  2021-02       Impact factor: 4.452

3.  COPS5 Conferred the Platinum Resistance in Epithelial Ovarian Cancer.

Authors:  Hongqin Zhang; Tianqing Yan; Ailing Zhong; Lin Guo; Renquan Lu
Journal:  Curr Issues Mol Biol       Date:  2022-09-01       Impact factor: 2.976

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.